Avelumab and Merkel Cell Carcinoma: Examining the Evidence for Causation

From Public Health Surveillance to Occupational Exposure Assessment

The legacy of general health and science communication has long emphasized broad public awareness of infectious disease outbreaks, such as the Ebola virus epidemic in West Africa, where reporting focused on case counts, geographic spread, and containment measures. This foundation established a framework for understanding how environmental and biological exposures can influence population health outcomes. Transitioning from this heritage, the same principles of exposure assessment and risk communication now apply to occupational settings where chemical or pharmaceutical agents are encountered. In mass production environments, workers may face sustained contact with therapeutic compounds, including monoclonal antibodies like avelumab. The target query shifts attention to whether such occupational exposure correlates with elevated risk for Merkel cell carcinoma, a rare skin cancer. Studies examining this potential causation investigate the relationship between avelumab—an immune checkpoint inhibitor used in cancer treatment—and subsequent malignancy development. This pivot from general health context to specific occupational exposure concern requires careful evaluation of exposure duration, concentration levels, and biological plausibility, without invoking mechanistic claims. The transition thus reframes legacy public health vigilance into a focused inquiry on workplace safety and long-term risk monitoring for production personnel.

Avelumab: A Therapeutic Agent for Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Merkel Cell Carcinoma: Etiology and Epidemiology

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab and pembrolizumab, offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy, and 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/).

Evidence for Causation: Avelumab as Treatment, Not Cause

The mechanistic pathways linking avelumab to Merkel cell carcinoma are primarily therapeutic rather than causative. Avelumab is used to treat MCC by blocking PD-L1, thereby enhancing the immune system's ability to attack cancer cells. The evidence does not indicate that avelumab causes MCC; rather, it is a treatment for the disease. The reported adverse effects of avelumab include immune-related adverse events, which can occur due to the drug's mechanism of action (https://pubmed.ncbi.nlm.nih.gov/34445385/). For patients who are refractory to avelumab, treatment options include combined ipilimumab plus nivolumab, which has shown efficacy in avelumab-refractory MCC in retrospective studies (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). In a multicenter study of the prospective skin cancer registry ADOREG, ipilimumab plus nivolumab was evaluated in avelumab-refractory MCC patients (https://pubmed.ncbi.nlm.nih.gov/36450381/). Similarly, a retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC reported outcomes (https://pubmed.ncbi.nlm.nih.gov/35877101/). In one report, three out of five patients with avelumab-refractory MCC responded to combined ipilimumab/nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Risk Context and Clinical Considerations

Regarding risk anchors, the adequacy of warnings about avelumab and MCC is centered on its approved use as a treatment, not as a causative agent. The evidence does not support a causal link between avelumab exposure and the development of MCC. Instead, avelumab is indicated for the treatment of existing MCC. Causation-related considerations for affected patients focus on the drug's role in managing the disease, including its efficacy and potential adverse effects. The timeline between exposure and documented harm is relevant to immune-related adverse events that may occur during treatment, rather than to the initiation of MCC. For patients who experience progression on avelumab, the timeline of treatment failure and subsequent therapy is documented in clinical studies (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). In summary, the evidence indicates that avelumab is a therapeutic agent for metastatic MCC, with no evidence suggesting it causes the disease. The drug's pharmacology involves PD-L1 inhibition, and its adverse effects include immune-related events. For patients who do not respond to avelumab, alternative immunotherapies are available. The risk narrative should emphasize that avelumab is a treatment for MCC, not a trigger, and that warnings and considerations are appropriately focused on its therapeutic use and potential side effects.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma, not a cause. It works by blocking PD-L1 to help the immune system attack cancer cells. Studies show no evidence that avelumab causes MCC; rather, it is used to treat existing disease.

What are the risks of avelumab treatment?

The main risks are immune-related adverse events due to its mechanism of action, such as inflammation of organs. These side effects are manageable and are part of the drug's approved safety profile. Avelumab does not increase the risk of developing MCC.

What should I do if I have been exposed to avelumab and developed Merkel cell carcinoma?

If you have documented avelumab exposure and a confirmed MCC diagnosis, you may request an independent eligibility review through the Information Registry. However, note that avelumab is used to treat MCC, and there is no evidence it causes the disease.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.